Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts.

Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts.

Shares of Avadel Pharmaceuticals PLC (NASDAQ:AVDL) rose 4.7% following a key legal victory, as a U.S. appeals court ...

Investing.com -- Avadel Pharmaceuticals PLC (NASDAQ: AVDL) stock rose 4.7% after a U.S. appeals court unanimously upheld the FDA’s approval of LUMRYZ, the company’s once-at-bedtime treatment for ...

Avadel Pharmaceuticals (AVDL) announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit affirmed a ...

ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug, ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Needham analyst ...

PLYMOUTH MEETING, Pa., June 11, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an ...

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 BP1.15205 is a potentially best-in ...

Narcolepsy disrupts more than sleep—it affects daily life. Learn about causes, symptoms, diagnosis, and the latest treatment strategies.

Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled trial, partic ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy attacks in narcolepsy, a phase 3 trial suggests.